<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000942.pub3" GROUP_ID="PREG" ID="229499081020064954" MERGED_FROM="" MODIFIED="2014-03-28 10:32:05 +0000" MODIFIED_BY="Leanne Jones" REVIEW_NO="0216" REVMAN_SUB_VERSION="5.2.8 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2014-03-28 10:32:05 +0000" MODIFIED_BY="Leanne Jones">
<TITLE MODIFIED="2012-07-11 16:15:52 +0100" MODIFIED_BY="[Empty name]">Amnioinfusion for third trimester preterm premature rupture of membranes</TITLE>
<CONTACT MODIFIED="2014-03-28 10:32:05 +0000" MODIFIED_BY="Leanne Jones"><PERSON ID="15917" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>G Justus</FIRST_NAME><LAST_NAME>Hofmeyr</LAST_NAME><POSITION>Director/Hon. Professor, Effective Care Research Unit</POSITION><EMAIL_1>justhof@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology, East London Hospital Complex</DEPARTMENT><ORGANISATION>University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health</ORGANISATION><ADDRESS_1>Frere and Cecilia Makiwane Hospitals</ADDRESS_1><ADDRESS_2>Private Bag X 9047</ADDRESS_2><CITY>East London</CITY><ZIP>5200</ZIP><REGION>Eastern Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 43 7092483</PHONE_1><PHONE_2>+27 83 2809402</PHONE_2><FAX_1>+27 43 7092483</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-03-28 10:32:05 +0000" MODIFIED_BY="Leanne Jones"><PERSON ID="15917" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>G Justus</FIRST_NAME><LAST_NAME>Hofmeyr</LAST_NAME><POSITION>Director/Hon. Professor, Effective Care Research Unit</POSITION><EMAIL_1>justhof@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology, East London Hospital Complex</DEPARTMENT><ORGANISATION>University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health</ORGANISATION><ADDRESS_1>Frere and Cecilia Makiwane Hospitals</ADDRESS_1><ADDRESS_2>Private Bag X 9047</ADDRESS_2><CITY>East London</CITY><ZIP>5200</ZIP><REGION>Eastern Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 43 7092483</PHONE_1><PHONE_2>+27 83 2809402</PHONE_2><FAX_1>+27 43 7092483</FAX_1></ADDRESS></PERSON><PERSON ID="3A175D1E82E26AA20164DA257C2077F8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ahizechukwu</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Eke</LAST_NAME><EMAIL_1>ahizeeke2nd@yahoo.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>Michigan State University School of Medicine/Sparrow Hospital</ORGANISATION><ADDRESS_1>1322 East Michigan Avenue</ADDRESS_1><ADDRESS_2>Suite 220</ADDRESS_2><CITY>Lansing</CITY><ZIP>48912</ZIP><REGION>Michigan</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="16495233707895187386090810093217" ROLE="AUTHOR"><FIRST_NAME>Theresa</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Lawrie</LAST_NAME><SUFFIX>MBBCH, PhD</SUFFIX><POSITION>Senior Researcher</POSITION><EMAIL_1>tess@lawrie.com</EMAIL_1><MOBILE_PHONE>+447826939464</MOBILE_PHONE><ADDRESS><DEPARTMENT>Cochrane Gynaecological Cancer Group</DEPARTMENT><ORGANISATION>Royal United Hospital</ORGANISATION><ADDRESS_1>Education Centre</ADDRESS_1><CITY>Bath</CITY><ZIP>BA13NG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1225 428021</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-01-13 13:56:38 +0000" MODIFIED_BY="Sonja Henderson">
<UP_TO_DATE>
<DATE DAY="2" MONTH="12" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="12" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="12" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-02-05 15:50:28 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-01-13 13:59:47 +0000" MODIFIED_BY="Leanne V Jones">
<DATE DAY="13" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>Two studies previously in ongoing have been excluded (<LINK REF="STD-Roberts_x003a_-AMIPROM" TYPE="STUDY">Roberts: AMIPROM</LINK>; <LINK REF="STD-Vergani-2007" TYPE="STUDY">Vergani 2007</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-02-05 15:50:28 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>Search updated. No new trials identified. Title changed from "<I>Amnioinfusion for preterm premature rupture of membranes</I>" to "<I>Amnioinfusion for third trimester preterm premature rupture of membranes</I>". See <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK> for more details. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-12-17 20:14:30 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-07-11 16:12:53 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>New authors helped to prepare this update. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-12-17 20:14:30 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="1" YEAR="2011"/>
<DESCRIPTION>
<P>Search updated, one new trial identified (<LINK REF="STD-Singla-2010" TYPE="STUDY">Singla 2010</LINK>) and included. We have also included three trials previously awaiting classification (<LINK REF="STD-Gonzalez-2001" TYPE="STUDY">Gonzalez 2001</LINK>; <LINK REF="STD-Puertas-2007" TYPE="STUDY">Puertas 2007</LINK>; <LINK REF="STD-Tranquilli-2005" TYPE="STUDY">Tranquilli 2005</LINK>).</P>
<P>We have also assessed the remaining trial reports from the previous search (previously in 'awaiting classification'), resulting in four excluded studies (<LINK REF="STD-De-Santis-2003" TYPE="STUDY">De Santis 2003</LINK>; <LINK REF="STD-Gowri-2004" TYPE="STUDY">Gowri 2004</LINK>; <LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>; <LINK REF="STD-Mino-1999" TYPE="STUDY">Mino 1999</LINK>) and two ongoing studies (Roberts: AMIPROMa; Vergani 2007a).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-18 11:18:12 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="7" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details edited.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-12-17 20:14:30 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated. Nine reports added to Studies awaiting classification (<LINK REF="STD-De-Santis-2003" TYPE="STUDY">De Santis 2003</LINK>; <LINK REF="STD-Gonzalez-2001" TYPE="STUDY">Gonzalez 2001</LINK>; <LINK REF="STD-Gowri-2004" TYPE="STUDY">Gowri 2004</LINK>; Mino 1997a; <LINK REF="STD-Mino-1999" TYPE="STUDY">Mino 1999</LINK>; Roberts 2006; <LINK REF="STD-Puertas-2007" TYPE="STUDY">Puertas 2007</LINK>; <LINK REF="STD-Tranquilli-2005" TYPE="STUDY">Tranquilli 2005</LINK>; Vergani 2007a).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-09-11 15:04:27 +0100" MODIFIED_BY="Sonja L  Henderson">
<DATE DAY="31" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of the Witwatersrand</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>South African Medical research Council</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>UNDP/UNFPA/WHO/World Bank (HRP)</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-03-28 10:29:26 +0000" MODIFIED_BY="Leanne V Jones">
<SUMMARY MODIFIED="2011-10-28 06:38:54 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-04-03 07:40:10 +0100" MODIFIED_BY="[Empty name]">Amnioinfusion for preterm premature rupture of membranes</TITLE>
<SUMMARY_BODY MODIFIED="2011-10-28 06:38:54 +0100" MODIFIED_BY="[Empty name]">
<P>There is some evidence to show that restoring amniotic fluid volume with saline or a similar fluid (amnioinfusion) following preterm premature rupture of the membranes (PPROM) may be beneficial for preterm babies (by preventing infection, lung damage and death) and mothers (by preventing infection of the womb after childbirth). However, current evidence is insufficient to recommend amnioinfusion for routine use in PPROM.</P>
<P>Preterm premature rupture of membranes is the single most identifiable cause of preterm labour. The sac (membranes) surrounding the baby and fluid in the womb (uterus) usually breaks (ruptures) during labour. If the membranes rupture before labour and preterm (before 37 weeks) the baby has an increased risk of infection. Reduced fluid around the baby also increases the chance of the umbilical cord being compressed, which can reduce the baby's supply of nutrients and oxygen. In addition, insufficient fluid in the womb may interfere with normal lung development in very small babies and can cause fetal distress, with changes in heart rate. Extra liquid can be injected through the woman's vagina (transcervical amnioinfusion) or abdomen (transabdominal amnioinfusion) into the womb, providing more liquid to surround the baby. The review of five randomised controlled trials (with data from a total of 241 participants analysed) found some evidence to show that amnioinfusion with a saline solution may improve health outcomes and be beneficial for babies and mothers following PPROM. However, the evidence is currently insufficient to recommend its routine use because of the limited number of trials and low numbers of women in the trials.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-03-18 11:18:09 +0000" MODIFIED_BY="Heather Maxwell">
<ABS_BACKGROUND MODIFIED="2011-04-04 09:27:54 +0100" MODIFIED_BY="[Empty name]">
<P>Preterm premature rupture of membranes (PPROM) is a leading cause of perinatal morbidity and mortality. Amnioinfusion aims to restore amniotic fluid volume by infusing a solution into the uterine cavity.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-04-04 09:27:59 +0100" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to assess the effects of amnioinfusion for PPROM on perinatal and maternal morbidity and mortality.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-12-02 14:35:59 +0000" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (2 December 2013).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-03-18 11:18:09 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomised trials of amnioinfusion compared with no amnioinfusion in women with PPROM.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-11-02 12:27:59 +0000" MODIFIED_BY="Denise Atherton">
<P>Three review authors independently assessed trials for inclusion. Two review authors independently assessed trial quality and extracted data. Data were checked for accuracy.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-01-30 11:00:06 +0000" MODIFIED_BY="[Empty name]">
<P>We included five trials, of moderate quality, but we only analysed data from four studies (with a total of 241 participants). One trial did not contribute any data to the review.</P>
<P>Transcervical amnioinfusion improved fetal umbilical artery pH at delivery (mean difference 0.11; 95% confidence interval (CI) 0.08 to 0.14; one trial, 61 participants) and reduced persistent variable decelerations during labour (risk ratio (RR) 0.52; 95% CI 0.30 to 0.91; one trial, 86 participants).</P>
<P>Transabdominal amnioinfusion was associated with a reduction in neonatal death (RR 0.30; 95% CI 0.14 to 0.66; two trials, 94 participants), neonatal sepsis (RR 0.26; 95% CI 0.11 to 0.61; one trial, 60 participants), pulmonary hypoplasia (RR 0.22; 95% CI 0.06 to 0.88; one trial, 34 participants) and puerperal sepsis (RR 0.20; 95% CI 0.05 to 0.84; one trial, 60 participants). Women in the amnioinfusion group were also less likely to deliver within seven days of membrane rupture (RR 0.18; 95% CI 0.05 to 0.70; one trial, 34 participants). These results should be treated with circumspection as the positive findings were mainly due to one trial with unclear allocation concealment.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-09-24 17:19:58 +0100" MODIFIED_BY="[Empty name]">
<P>These results are encouraging but are limited by the sparse data and unclear methodological robustness, therefore further evidence is required before amnioinfusion for PPROM can be recommended for routine clinical practice.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-03-28 10:29:26 +0000" MODIFIED_BY="Leanne V Jones">
<BACKGROUND MODIFIED="2014-03-26 12:21:30 +0000" MODIFIED_BY="Leanne V Jones">
<CONDITION MODIFIED="2011-05-18 14:01:07 +0100" MODIFIED_BY="[Empty name]">
<P>Preterm premature rupture of membranes (PPROM) remains the single most identifiable cause of preterm labour and a major contributor to perinatal mortality and morbidity. Oligohydramnios (reduced amniotic fluid volume) following PPROM is associated with a higher risk of chorioamnionitis, neonatal fetal infection and cord compression (<LINK REF="REF-Keirse-1989" TYPE="REFERENCE">Keirse 1989</LINK>; <LINK REF="REF-Vintzileos-1985" TYPE="REFERENCE">Vintzileos 1985</LINK>). Umbilical cord compression may cause persistent variable fetal heart rate decelerations (<LINK REF="REF-Gabbe-1976" TYPE="REFERENCE">Gabbe 1976</LINK>). Oligohydramnios is also the most important predictor of perinatal mortality in very early PPROM and adequate residual amniotic fluid plays a critical role in determining the prevalence of pulmonary hypoplasia, which is a major cause of death in these babies (<LINK REF="REF-Vergani-1994" TYPE="REFERENCE">Vergani 1994</LINK>; <LINK REF="REF-Vintzileos-1985" TYPE="REFERENCE">Vintzileos 1985</LINK>). Abnormal neurological outcomes and postural deformities in the neonate may also occur as a consequence of PPROM (<LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-03-26 11:22:04 +0000" MODIFIED_BY="Leanne V Jones">
<P>Saline fluid or Ringers lactate/Hartmans is infused transcervically through a catheter into the uterine cavity, or transabdominally, through a narrow gauge needle. Amnioinfusion was first described as a method of preventing or relieving umbilical cord compression during labour (<LINK REF="REF-Miyazaki-1983" TYPE="REFERENCE">Miyazaki 1983</LINK>). The technique has since been used prophylactically in various conditions associated with oligohydramnios, including impaired intrauterine growth and PPROM. Amnioinfusion has been shown to prolong the latency period in second trimester PPROM (<LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>; <LINK REF="REF-Ogunyemi-2002" TYPE="REFERENCE">Ogunyemi 2002</LINK>; <LINK REF="REF-Turhan-2002" TYPE="REFERENCE">Turhan 2002</LINK>), improve perinatal survival (<LINK REF="REF-Locatelli-2006" TYPE="REFERENCE">Locatelli 2006</LINK>; <LINK REF="REF-Ogunyemi-2002" TYPE="REFERENCE">Ogunyemi 2002</LINK>) and decrease rates of pulmonary hypoplasia (<LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>). Combined with antibiotics and without, it has been used to treat and to prevent infection following premature rupture of membranes (<LINK REF="REF-Goodlin-1981" TYPE="REFERENCE">Goodlin 1981</LINK>; <LINK REF="REF-Monahan-1995" TYPE="REFERENCE">Monahan 1995</LINK>; <LINK REF="REF-Ogita-1988" TYPE="REFERENCE">Ogita 1988</LINK>). In a Cochrane review on amnioinfusion for suspected or potential cord compression in labour at term, amnioinfusion improved short-term measures of neonatal outcome, reduced the use of caesarean section and reduced maternal puerperal sepsis (<LINK REF="REF-Hofmeyr-2012" TYPE="REFERENCE">Hofmeyr 2012</LINK>). A subcutaneously implanted amniotic fluid replacement port system has been developed for long-term amnioinfusion in women with preterm premature rupture of the membranes (<LINK REF="REF-Tchirikov-2010" TYPE="REFERENCE">Tchirikov 2010</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-03-18 11:21:23 +0000" MODIFIED_BY="Heather Maxwell">
<P>Restoring the amniotic fluid volume cushions the fetus, thereby preventing mechanical compression of the umbilical cord and reducing fetal distress. It may prevent fetal lung hypoplasia in PPROM by preventing mechanical compression of the fetal thorax and enabling normal amniotic fluid flow into the fetal lungs (<LINK REF="STD-Tranquilli-2005" TYPE="STUDY">Tranquilli 2005</LINK>). This effect occurs mainly in the second trimester and is considered in a separate review (<LINK REF="REF-Van-Teeffelen-2013" TYPE="REFERENCE">Van Teeffelen 2013</LINK>). Likewise, by preventing mechanical compression of the fetus, amnioinfusion may prevent postural deformities. In addition, the infused fluid may prevent intrauterine infection, possibly by the anti-bacterial effect of saline, or a diluent effect. Improvements in fetal ductus venosus and umbilical artery flow have been demonstrated following amnioinfusion for PPROM (<LINK REF="REF-Hsu-2009" TYPE="REFERENCE">Hsu 2009</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-03-26 12:21:30 +0000" MODIFIED_BY="Leanne V Jones">
<P>Evidence from cohort studies suggests that replenishing the amniotic fluid volume in pregnancies complicated by PPROM is beneficial to mother and child. However, amnioinfusion is an invasive procedure and not without potential risks, thus a thorough evaluation of randomised controlled trials is required.</P>
<P>[<I>'Amnioinfusion for cord compression'</I> (<LINK REF="REF-Hofmeyr-2012" TYPE="REFERENCE">Hofmeyr 2012</LINK>), '<I>Prophylactic versus therapeutic amnioinfusion' </I>(<LINK REF="REF-Novikova-2012" TYPE="REFERENCE">Novikova 2012</LINK>), <I>and 'Amnioinfusion for meconium-stained liquor' </I>(<LINK REF="REF-Hofmeyr-2014" TYPE="REFERENCE">Hofmeyr 2014</LINK>), <I>are separate reviews</I>.]</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-04-03 07:45:28 +0100" MODIFIED_BY="[Empty name]">
<P>To assess from the best available evidence the effects of amnioinfusion for preterm premature rupture of membranes on perinatal morbidity and mortality.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-03-28 10:29:26 +0000" MODIFIED_BY="Leanne V Jones">
<SELECTION_CRITERIA MODIFIED="2014-03-28 10:29:26 +0000" MODIFIED_BY="Leanne V Jones">
<CRIT_STUDIES MODIFIED="2014-01-13 15:13:16 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical trials comparing the effect of amnioinfusion for third trimester preterm premature rupture of the membranes before 37 weeks with a control group (no amnioinfusion); random allocation to treatment and control groups, with adequate allocation concealment; violations of allocated management and exclusions after allocation not sufficient to materially affect outcomes. Quasi-randomised (alternate allocation), cross-over and cluster trials were not considered eligible for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-03-31 11:18:47 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant women with preterm premature rupture of membranes.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Amnioinfusion compared with no amnioinfusion.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-03-28 10:29:26 +0000" MODIFIED_BY="Leanne V Jones">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-10-28 06:39:13 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Indicators of fetal condition, e.g. persistent variable decelerations, Apgar scores, cord arterial pH at birth.</LI>
<LI>Neonatal morbidity including infection, lung hypoplasia, abnormal neurological outcomes and postural deformities.</LI>
<LI>Perinatal mortality.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-03-28 10:29:26 +0000" MODIFIED_BY="Leanne V Jones">
<UL>
<LI>Mode of delivery.</LI>
<LI>Indications for delivery.</LI>
<LI>Latency period from amnioinfusion to delivery.</LI>
<LI>Maternal morbidity, e.g. endometritis, postpartum temperature greater than 38°C.</LI>
<LI>Birthweight.</LI>
<LI>Admission to neonatal intensive or high care unit.</LI>
</UL>
<P>We considered outcomes separately for transcervical and transabdominal amnioinfusion.</P>
<P/>
<P>The methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-03-10 10:30:12 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-03-10 10:30:12 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (2 December 2013). </P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>monthly searches of Embase;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords. </P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-01-14 12:18:32 +0000" MODIFIED_BY="[Empty name]">
<P>No new studies have been included for this update (2014).</P>
<P>For methods used in the previous version of this review, please see <LINK REF="REF-Hofmeyr-2011" TYPE="REFERENCE">Hofmeyr 2011</LINK>.</P>
<P>For methods to be used in the next update, see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<STUDY_SELECTION MODIFIED="2014-01-14 12:18:14 +0000" MODIFIED_BY="Leanne V Jones">
<P>T Lawrie (TL), AC Eke (ACE) and GJ Hofmeyr (GJH) independently assessed for inclusion all potential studies. No studies were identified from the updated search. Two studies previously in ongoing were excluded (<LINK REF="STD-Roberts_x003a_-AMIPROM" TYPE="STUDY">Roberts: AMIPROM</LINK>; <LINK REF="STD-Vergani-2007" TYPE="STUDY">Vergani 2007</LINK>). We resolved any disagreement through discussion. We evaluated trials under consideration for methodological quality and appropriateness for inclusion according to the prespecified selection criteria, without consideration of their results.</P>
</STUDY_SELECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-03-18 11:27:17 +0000" MODIFIED_BY="Heather Maxwell">
<STUDY_DESCRIPTION MODIFIED="2011-10-28 06:27:10 +0100" MODIFIED_BY="[Empty name]">
<P>In total, we have included five studies; three in the transcervical amnioinfusion comparison (<LINK REF="STD-Gonzalez-2001" TYPE="STUDY">Gonzalez 2001</LINK>; <LINK REF="STD-Nageotte-1985" TYPE="STUDY">Nageotte 1985</LINK>; <LINK REF="STD-Puertas-2007" TYPE="STUDY">Puertas 2007</LINK>) and two in the transabdominal comparison (<LINK REF="STD-Singla-2010" TYPE="STUDY">Singla 2010</LINK>; <LINK REF="STD-Tranquilli-2005" TYPE="STUDY">Tranquilli 2005</LINK>). One included study contributed no data (<LINK REF="STD-Gonzalez-2001" TYPE="STUDY">Gonzalez 2001</LINK>). <I>See</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. The gestational age range for recruitment to the transcervical trials was 26 to 36+ weeks and in the transabdominal trials, 24 to 34 weeks. Transcervical amnioinfusion was performed in a total of 72 women versus 75 controls (excluding unusable data from <LINK REF="STD-Gonzalez-2001" TYPE="STUDY">Gonzalez 2001</LINK>) and transabdominal amnioinfusion was performed in 47 women versus 47 controls; thus participant numbers for this review are small.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-03-18 11:25:37 +0000" MODIFIED_BY="Heather Maxwell">
<P>All included studies were randomised trials. <I>See</I> <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for a summary of 'Risk of bias' assessments.<U>
<B>
<BR/>
</B>
</U>
</P>
<ALLOCATION MODIFIED="2014-03-18 11:22:46 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomisation was by random number table in <LINK REF="STD-Puertas-2007" TYPE="STUDY">Puertas 2007</LINK> and was computer-generated in <LINK REF="STD-Tranquilli-2005" TYPE="STUDY">Tranquilli 2005</LINK> and <LINK REF="STD-Singla-2010" TYPE="STUDY">Singla 2010</LINK>; the method of randomisation and group allocation was not described in <LINK REF="STD-Nageotte-1985" TYPE="STUDY">Nageotte 1985</LINK> and <LINK REF="STD-Gonzalez-2001" TYPE="STUDY">Gonzalez 2001</LINK>. Allocation concealment was described in two trials (<LINK REF="STD-Puertas-2007" TYPE="STUDY">Puertas 2007</LINK>; <LINK REF="STD-Tranquilli-2005" TYPE="STUDY">Tranquilli 2005</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-01-30 11:08:20 +0000" MODIFIED_BY="Leanne V Jones">
<P>Partial blinding was described in two trials (<LINK REF="STD-Nageotte-1985" TYPE="STUDY">Nageotte 1985</LINK>; <LINK REF="STD-Puertas-2007" TYPE="STUDY">Puertas 2007</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-03-18 11:24:41 +0000" MODIFIED_BY="Heather Maxwell">
<P>Incomplete outcome data were noted in the randomised clinical trial by Gonzalez et al. This is because it is an abstract only publication, hence provided insufficient detail for assessment (<LINK REF="STD-Gonzalez-2001" TYPE="STUDY">Gonzalez 2001</LINK>). Five post-randomisation exclusions: three for non-vertex presentation and two for fetal distress were noted in the randomised trial by Nageotte et al (<LINK REF="STD-Nageotte-1985" TYPE="STUDY">Nageotte 1985</LINK>). Otherwise, outcome data were complete for <LINK REF="STD-Puertas-2007" TYPE="STUDY">Puertas 2007</LINK>, <LINK REF="STD-Singla-2010" TYPE="STUDY">Singla 2010</LINK> and <LINK REF="STD-Tranquilli-2005" TYPE="STUDY">Tranquilli 2005</LINK>.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-02-05 11:18:13 +0000" MODIFIED_BY="Leanne V Jones">
<P>In the randomised clinical trial by Tranquilli et al, the authors did not report the mode of delivery, Apgar scores or cord arterial pH for the babies delivered (<LINK REF="STD-Tranquilli-2005" TYPE="STUDY">Tranquilli 2005</LINK>). No selective reporting was found in the <LINK REF="STD-Puertas-2007" TYPE="STUDY">Puertas 2007</LINK> and <LINK REF="STD-Singla-2010" TYPE="STUDY">Singla 2010</LINK> trials. There was insufficient information to assess selective reporting in <LINK REF="STD-Gonzalez-2001" TYPE="STUDY">Gonzalez 2001</LINK> and <LINK REF="STD-Nageotte-1985" TYPE="STUDY">Nageotte 1985</LINK>.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-03-18 11:25:37 +0000" MODIFIED_BY="Heather Maxwell">
<P>Another source of bias was noted in the randomised clinical trial by Puertas et al, where more carriers of group B streptococcal were noted in control group (14 women versus seven women) (<LINK REF="STD-Puertas-2007" TYPE="STUDY">Puertas 2007</LINK>). Even though all these women with Group B streptococcal infection received prophylactic intrapartum antibiotics, the higher incidence of Group B <I>Streptococcus</I> in the control group was a source of bias for the trial. No other biases were reported for <LINK REF="STD-Singla-2010" TYPE="STUDY">Singla 2010</LINK> and <LINK REF="STD-Tranquilli-2005" TYPE="STUDY">Tranquilli 2005</LINK>. There was insufficient information to assess other sources of bias in <LINK REF="STD-Gonzalez-2001" TYPE="STUDY">Gonzalez 2001</LINK> and <LINK REF="STD-Nageotte-1985" TYPE="STUDY">Nageotte 1985</LINK>.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-03-18 11:27:17 +0000" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">1. Transcervical amnioinfusion</HEADING>
<P>
<I>Transcervical </I>amnioinfusion improved fetal umbilical artery pH at delivery (mean difference (MD) 0.11; 95% confidence interval (CI) 0.08 to 0.14; one trial, 61 participants; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) and reduced persistent variable decelerations during labour (risk ratio (RR) 0.52; 95% CI 0.30 to 0.91; one trial, 86 participants; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). No significant differences in the rates of caesarean section, low Apgar scores, neonatal death or infectious morbidity were detected.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Transabdominal amnioinfusion</HEADING>
<P>
<I>Transabdominal</I> amnioinfusion was associated with a reduction in neonatal death (RR 0.30; 95% CI 0.14 to 0.66; two trials, 94 women; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>), neonatal infection/sepsis (RR 0.26; 95% CI 0.11 to 0.61; one trial, 60 participants; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), and pulmonary hypoplasia (RR 0.22; 95% CI 0.06 to 0.88; one trial, 34 participants; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). Women in the amnioinfusion group were also less likely to deliver within seven days of membrane rupture (RR 0.18; 95% CI 0.05 to 0.70; one trial, 34 participants; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) and were less likely to experience puerperal sepsis (RR 0.20; 95% CI 0.05 to 0.84; one trial, 60 participants; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>). There were no significant differences between groups regarding birthweight, gestational age at delivery, admission to neonatal intensive care and neurological sequelae. Fetal distress was diagnosed less frequently in the amnioinfusion group than the control group (RR 0.27; 95% CI 0.08 to 0.88; one trial, 60 participants; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), but in the absence of blinding this outcome is at risk of bias.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-01-28 14:21:00 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-10-06 10:46:27 +0100" MODIFIED_BY="[Empty name]">
<P>Transabdominal amnioinfusion following preterm premature rupture of the membranes (PPROM) resulted in better neonatal outcomes (decreased sepsis, infection and death) and decreased puerperal sepsis than conventional management. The data contributing to these outcomes were mainly from one trial (<LINK REF="STD-Singla-2010" TYPE="STUDY">Singla 2010</LINK>). Transcervical amnioinfusion was associated with improved fetal heart rate patterns and umbilical cord blood pH results, but improvements in substantive clinical outcomes were not statistically significant.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-01-28 14:21:00 +0000" MODIFIED_BY="Denise Atherton">
<P>These results are not conclusive due to the small numbers of trials and participants. In addition, the numbers are too small to detect rare potential adverse events. The lower threshold of gestational age at which amnioinfusion may be of benefit is not known. </P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-03-29 11:23:42 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence is of mainly moderate quality (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) and limitations can largely be attributed to the small size of studies and the lack of blinding to group allocation.</P>
</QUALITY_OF_EVIDENCE>
<AGREEMENT MODIFIED="2011-05-18 13:01:58 +0100" MODIFIED_BY="[Empty name]">
<P>This evidence supports the positive findings of the non-randomised studies conducted to date.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-01-13 11:47:01 +0000" MODIFIED_BY="Denise Atherton">
<IMPLICATIONS_PRACTICE MODIFIED="2011-06-17 12:27:40 +0100" MODIFIED_BY="Denise Atherton">
<P>There is currently insufficient evidence to guide clinical practice concerning the use of amnioinfusion for preterm premature rupture of the membranes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-01-13 11:47:01 +0000" MODIFIED_BY="[Empty name]">
<P>Larger trials are needed to confirm and extend the findings of the trials reviewed here. Long-term follow-up of babies is desirable, especially with regard to neurological sequelae and development. Future trials and reviews may need to be stratified according to gestational age to determine whether there is a threshold for benefits and risks.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-03-07 10:11:49 +0000" MODIFIED_BY="[Empty name]">
<P>Sara Roden-Scott, Julieta Mattera and Nadia Bondarczuk for providing a translation for the Spanish trial report of <LINK REF="STD-Mino-1999" TYPE="STUDY">Mino 1999</LINK>.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-01-14 12:52:13 +0000" MODIFIED_BY="[Empty name]">
<P>GJ Hofmeyr prepared the review and maintains it. For the 2011 update, G Essilfie-Appiah assisted with the selection of studies and data extraction. T Lawrie assisted with study selection, data extraction and the text of the updated review. For the 2014 update, AC Eke assisted with the selection of studies, data extraction and the text of the updated review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-02-05 15:54:52 +0000" MODIFIED_BY="[Empty name]">
<P>In order to eliminate overlap between this review and a separate review (<LINK REF="REF-Van-Teeffelen-2013" TYPE="REFERENCE">Van Teeffelen 2013</LINK>), the title of this review has been changed from "<I>Amnioinfusion for preterm premature rupture of membranes</I>" to "<I>Amnioinfusion for third trimester preterm premature rupture of membranes</I>".</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-03-26 12:22:23 +0000" MODIFIED_BY="Leanne V Jones">
<STUDIES MODIFIED="2014-03-10 10:32:54 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-04-07 10:12:40 +0100" MODIFIED_BY="Jill Hampson">
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez-2001" MODIFIED="2011-04-07 10:12:27 +0100" MODIFIED_BY="Jill Hampson" NAME="Gonzalez 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-04-07 10:12:27 +0100" MODIFIED_BY="Jill Hampson" NOTES="&lt;p&gt;Gonzalez R, Malde J, Carrillo MP, Sancho-Minano J, Garrote A, Munoz A et al. The use of amnioinfusion in preterm deliveries. Preliminary results [abstract]. Journal of Perinatal Medicine 2001;29 Suppl 1(Pt 2):629&lt;/p&gt;" NOTES_MODIFIED="2011-04-07 10:12:27 +0100" NOTES_MODIFIED_BY="Jill Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez R, Malde J, Carrillo MP, Sancho-Minano J, Garrote A, Munoz A, et al</AU>
<TI>The use of amnioinfusion in preterm deliveries. Preliminary results [abstract]</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>2001</YR>
<VL>29 Suppl 1</VL>
<NO>Pt 2</NO>
<PG>629</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nageotte-1985" NAME="Nageotte 1985" YEAR="01433">
<REFERENCE NOTES="&lt;p&gt;[1433]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nageotte MP, Freeman RK, Garite TJ, Dorchester W</AU>
<TI>Prophylactic intrapartum amnioinfusion in patients with preterm premature rupture of membranes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1985</YR>
<VL>153</VL>
<PG>557-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puertas-2007" MODIFIED="2011-03-23 10:17:14 +0000" MODIFIED_BY="[Empty name]" NAME="Puertas 2007" YEAR="2006">
<REFERENCE MODIFIED="2009-09-11 12:27:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puertas A, Tirado P, Perez I, Lopez MS, Montoya F, Canizares JM, et al</AU>
<TI>Transcervical intrapartum amnioinfusion for preterm premature rupture of the membranes</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2007</YR>
<VL>131</VL>
<NO>1</NO>
<PG>40-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singla-2010" MODIFIED="2011-04-07 10:12:40 +0100" MODIFIED_BY="Jill Hampson" NAME="Singla 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-04-07 10:12:40 +0100" MODIFIED_BY="Jill Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singla A, Yadav P, Vaid NB, Suneja A, Faridi MMA</AU>
<TI>Transabdominal amnioinfusion in preterm premature rupture of membranes</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2010</YR>
<VL>108</VL>
<PG>199-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tranquilli-2005" MODIFIED="2009-09-11 12:27:24 +0100" MODIFIED_BY="[Empty name]" NAME="Tranquilli 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-09-11 12:27:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tranquilli AL, Giannubilo SR, Bezzeccheri V, Scagnoli C</AU>
<TI>Transabdominal amnioinfusion in preterm premature rupture of membranes: a randomised controlled trial</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>6</NO>
<PG>759-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-03-10 10:32:54 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-De-Santis-2003" MODIFIED="2009-09-11 12:27:24 +0100" MODIFIED_BY="[Empty name]" NAME="De Santis 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-09-11 12:27:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Santis M, Scavo M, Noia G, Masini L, Piersigilli F, Romagnoli C, et al</AU>
<TI>Transabdominal amnioinfusion treatment of severe oligohydramnios in preterm premature rupture of membranes at less than 26 gestational weeks</TI>
<SO>Fetal Diagnosis and Therapy</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>6</NO>
<PG>412-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gowri-2004" MODIFIED="2011-04-07 10:13:33 +0100" MODIFIED_BY="Jill Hampson" NAME="Gowri 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-04-07 10:13:33 +0100" MODIFIED_BY="Jill Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gowri R, Soundaraghavan S</AU>
<TI>Evaluation of transabdominal amnioinfusion in the antepartum management of oligohydramnios complicating preterm pregnancies</TI>
<SO>Journal of Obstetrics and Gynaecology of India</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>5</NO>
<PG>460-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-28 10:16:32 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-2000" MODIFIED="2011-03-28 10:15:55 +0100" MODIFIED_BY="[Empty name]" NAME="Locatelli 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-03-24 12:06:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli A, Vergani P, Di Pirro G, Doria V, Biffi A, Ghidini A</AU>
<TI>Role of amnioinfusion in the management of premature rupture of membranes at &lt; 26 weeks gestation</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>183</VL>
<PG>878-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-03-28 10:15:55 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mino-1999" MODIFIED="2011-10-28 06:40:02 +0100" MODIFIED_BY="Lynn Hampson" NAME="Mino 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-06-01 13:28:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mino M, Puertas A, Carrillo M, Santiago J, Herruzo A, Miranda J</AU>
<TI>Influence of amnioinfusion on variable or prolonged decelarations: a randomised study</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1997</YR>
<VL>76</VL>
<PG>95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-01 13:28:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mino M, Puertas A, Herruzo AJ, Miranda JA</AU>
<TI>Amnioinfusion in labor induction of term pregnancies with premature rupture of the membranes and low amniotic fluid</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1998</YR>
<VL>61</VL>
<PG>135-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-08 11:25:06 +0100" MODIFIED_BY="Lynn Hampson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mino M, Puertas A, Miranda JA, Herruzo AJ</AU>
<TI>Amnioinfusion in term labor with low amniotic fluid due to rupture of membranes: a new indication</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1999</YR>
<VL>82</VL>
<PG>29-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-28 06:40:02 +0100" MODIFIED_BY="Jill Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mino M, Puertas A, Mozas J, Carrillo Badillo MP, Rodríguez Oliver A, Miranda JA</AU>
<TI>A modification of the amniotic fluid index after amnioinfusion for infants with early rupture of membranes</TI>
<TO>Modificacion del indice de liquido amniotico tras amnioinfusion en gestantes con rotura prematura de membranas a termino</TO>
<SO>Acta Ginecologica</SO>
<YR>1997</YR>
<VL>51</VL>
<NO>1</NO>
<PG>11-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-01 13:28:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puertas A, Mino M, Carrillo M, Mozas J, Herruzo A, Miranda J</AU>
<TI>Influence of amnioinfusion on neonatal acid-base state: a randomized study</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica Supplement</SO>
<YR>1997</YR>
<VL>76</VL>
<PG>94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Roberts_x003a_-AMIPROM" MODIFIED="2014-03-10 10:32:54 +0000" MODIFIED_BY="[Empty name]" NAME="Roberts: AMIPROM" YEAR="2011">
<REFERENCE MODIFIED="2013-12-17 20:15:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Roberts D, Alfirevic Z, Bricker L, Beardsmore C, Paturi P, Taylor S, et al</AU>
<TI>Amnioinfusion in preterm premature rupture of membranes (AMIPROM study)</TI>
<SO>Current Controlled Trials (www.controlled-trials.com/)</SO>
<YR>(accessed 17 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-17 20:13:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts D, Beardsmore C, Shaw B, Martin W, Vause S, Bricker L, et al</AU>
<TI>AMIPROM: a pilot RCT on serial transabdominal amnioinfusion versus expectant management in very early PROM</TI>
<SO>Ultrasound in Obstetrics &amp; Gynecology</SO>
<YR>2012</YR>
<VL>40</VL>
<NO>Suppl 1</NO>
<PG>80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-10 10:32:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Roberts D, Vause S, Martin W, Green P, Walkinshaw S, Bricker L, et al</AU>
<TI>Amnioinfusion in very early preterm premature rupture of membranes - pregnancy, neonatal and maternal outcomes in the AMIPROM randomised controlled pilot study</TI>
<SO>Ultrasound in Obstetrics &amp; Gynecology</SO>
<YR>2013 Nov 21 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-17 20:13:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts D, Vause S, Martin W, Green P, Walkinshaw S, Bricker L, et al</AU>
<TI>Pregnancy outcomes in AMIPROM: a pilot RCT on serial transabdominal amnioinfusion versus expectant management in very early preterm prelabour rupture of membranes</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2013</YR>
<VL>120</VL>
<NO>Suppl s1</NO>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="ISRCTN" VALUE="ISRCTN81932589"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vergani-2007" MODIFIED="2013-12-17 20:14:30 +0000" MODIFIED_BY="[Empty name]" NAME="Vergani 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-17 20:14:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vergani P, Deprest J, Strobelt N, Locatelli A</AU>
<TI>Proposal for open randomized trial comparing perinatal outcome following expectant management versus amnioinfusion in PPROM &lt; 25 weeks with persistent oligohydramnios (amnioinfusion initiative)</TI>
<SO>Ultrasound in Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>30</VL>
<PG>541</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-03-23 12:56:59 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2013-12-17 20:14:30 +0000" MODIFIED_BY="Lynn Hampson"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-03-26 12:22:23 +0000" MODIFIED_BY="Leanne V Jones">
<ADDITIONAL_REFERENCES MODIFIED="2014-03-26 12:22:23 +0000" MODIFIED_BY="Leanne V Jones">
<REFERENCE ID="REF-Gabbe-1976" MODIFIED="2011-04-07 11:03:48 +0100" MODIFIED_BY="Jill Hampson" NAME="Gabbe 1976" TYPE="JOURNAL_ARTICLE">
<AU>Gabbe SG, Ettinger BB, Freeman RK, Martin CB</AU>
<TI>Umbilical cord compression associated with amniotomy: laboratory observations</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1976</YR>
<VL>126</VL>
<NO>3</NO>
<PG>353-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodlin-1981" MODIFIED="2011-04-07 11:04:04 +0100" MODIFIED_BY="Jill Hampson" NAME="Goodlin 1981" TYPE="JOURNAL_ARTICLE">
<AU>Goodlin RC</AU>
<TI>Intra-amniotic antibiotic infusions</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1981</YR>
<VL>139</VL>
<NO>8</NO>
<PG>975</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-10-31 13:45:40 +0000" MODIFIED_BY="Jill Hampson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated September 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2012" MODIFIED="2014-03-26 11:41:35 +0000" MODIFIED_BY="Leanne V Jones" NAME="Hofmeyr 2012" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Lawrie TA</AU>
<TI>Amnioinfusion for potential or suspected umbilical cord compression in labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-03-26 11:41:35 +0000" MODIFIED_BY="Leanne V Jones">
<IDENTIFIER MODIFIED="2014-03-26 11:41:35 +0000" MODIFIED_BY="Leanne V Jones" TYPE="DOI" VALUE="10.1002/14651858.CD000013.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2014" MODIFIED="2014-03-26 12:12:07 +0000" MODIFIED_BY="Leanne V Jones" NAME="Hofmeyr 2014" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Xu H, Eke AC</AU>
<TI>Amnioinfusion for meconium-stained liquor in labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-03-26 12:12:07 +0000" MODIFIED_BY="Leanne V Jones">
<IDENTIFIER MODIFIED="2014-03-26 12:12:07 +0000" MODIFIED_BY="Leanne V Jones" TYPE="DOI" VALUE="10.1002/14651858.CD000014.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hsu-2009" MODIFIED="2011-10-06 10:44:29 +0100" MODIFIED_BY="[Empty name]" NAME="Hsu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hsu TY, Hsu JJ, Fu HC, Ou CY, Tsai CC, Cheng BH, et al</AU>
<TI>The changes in Doppler indices of fetal ductus venosus and umbilical artery after amnioinfusion for women with preterm premature rupture of membranes before 26 weeks' gestation</TI>
<SO>Taiwan Journal of Obstetrics and Gynecology</SO>
<YR>2009</YR>
<VL>48</VL>
<NO>3</NO>
<PG>268-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keirse-1989" MODIFIED="2011-10-28 06:36:41 +0100" MODIFIED_BY="[Empty name]" NAME="Keirse 1989" TYPE="BOOK_SECTION">
<AU>Keirse MJNC, Ohlsson A, Treffers PE, Kanhai HHH</AU>
<TI>Prelabour rupture of the membranes preterm</TI>
<SO>Effective Care in Pregnancy and Childbirth</SO>
<YR>1989</YR>
<PG>666-93</PG>
<ED>Chalmers I, Enkin MW, Keirse MJNC</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Locatelli-2006" MODIFIED="2011-03-29 09:45:57 +0100" MODIFIED_BY="[Empty name]" NAME="Locatelli 2006" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli A, Ghidini A, Verderio M, Andreani M, Strobelt N, Pezzullo J, et al</AU>
<TI>Predictors of perinatal survival in a cohort of pregnancies with severe oligohydramnios due to premature rupture of membranes at &lt; 26 weeks managed with serial infusions</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2006</YR>
<VL>128</VL>
<NO>1-2</NO>
<PG>97-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miyazaki-1983" NAME="Miyazaki 1983" TYPE="JOURNAL_ARTICLE">
<AU>Miyazaki FS, Taylor NA</AU>
<TI>Saline amnioinfusion for relief of prolonged variable decelerations</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1983</YR>
<VL>146</VL>
<PG>670-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Monahan-1995" MODIFIED="2011-04-07 11:09:10 +0100" MODIFIED_BY="Jill Hampson" NAME="Monahan 1995" TYPE="JOURNAL_ARTICLE">
<AU>Monahan E, Katz VL, Cox RL</AU>
<TI>Amnioinfusion for preventing puerperal infection. A prospective study</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1995</YR>
<VL>40</VL>
<NO>10</NO>
<PG>721-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Novikova-2012" MODIFIED="2014-03-26 12:22:23 +0000" MODIFIED_BY="Leanne V Jones" NAME="Novikova 2012" TYPE="COCHRANE_REVIEW">
<AU>Novikova N, Hofmeyr GJ, Essilfie-Appiah G</AU>
<TI>Prophylactic versus therapeutic amnioinfusion for oligohydramnios in labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2014-03-26 12:22:23 +0000" MODIFIED_BY="Leanne V Jones">
<IDENTIFIER MODIFIED="2014-03-26 12:22:23 +0000" MODIFIED_BY="Leanne V Jones" TYPE="DOI" VALUE="10.1002/14651858.CD000176.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ogita-1988" MODIFIED="2011-10-28 06:37:04 +0100" MODIFIED_BY="[Empty name]" NAME="Ogita 1988" TYPE="JOURNAL_ARTICLE">
<AU>Ogita S, Imanaka M, Matsumoto M, Oka T, Sugawa T</AU>
<TI>Transcervical amnioinfusion of antibiotics: a basic study for managing premature rupture of membranes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>158</VL>
<NO>1</NO>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ogunyemi-2002" MODIFIED="2011-04-07 11:09:40 +0100" MODIFIED_BY="Jill Hampson" NAME="Ogunyemi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ogunyemi D, Thompson W</AU>
<TI>A case controlled study of serial transabdominal amnioinfusions in the management of second trimester oligohydramnios due to premature rupture of membranes</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2002</YR>
<VL>102</VL>
<NO>2</NO>
<PG>167-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2014-01-14 13:11:21 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tchirikov-2010" MODIFIED="2011-10-31 13:49:26 +0000" MODIFIED_BY="[Empty name]" NAME="Tchirikov 2010" TYPE="JOURNAL_ARTICLE">
<AU>Tchirikov M, Steetskamp J, Hohmann M, Koelbl H</AU>
<TI>Long-term amnioinfusion through a subcutaneously implanted amniotic fluid replacement port system for treatment of PPROM in humans</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2010</YR>
<VL>152</VL>
<PG>30-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turhan-2002" MODIFIED="2011-04-07 11:09:54 +0100" MODIFIED_BY="Jill Hampson" NAME="Turhan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Turhan NO, Atacan N</AU>
<TI>Antepartum prophylactic transabdominal amnioinfusion in preterm pregnancies complicated by oligohydramnios</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2002</YR>
<VL>76</VL>
<NO>1</NO>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Teeffelen-2013" MODIFIED="2014-03-10 10:33:20 +0000" MODIFIED_BY="[Empty name]" NAME="Van Teeffelen 2013" TYPE="COCHRANE_REVIEW">
<AU>Van Teeffelen S, Pajkrt E, Willekes C, Van Kuijk SMJ, Mol BWJ</AU>
<TI>Transabdominal amnioinfusion for improving fetal outcomes after oligohydramnios secondary to preterm prelabour rupture of membranes before 26 weeks</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2014-03-10 10:33:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-10 10:33:20 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD009952.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vergani-1994" MODIFIED="2011-04-07 15:26:40 +0100" MODIFIED_BY="Jill Hampson" NAME="Vergani 1994" TYPE="JOURNAL_ARTICLE">
<AU>Vergani P, Ghidini A, Locatelli A, Cavallone M, Ciarla I, Cappellini A, et al</AU>
<TI>Risk factors of pulmonary hypoplasia in second trimester premature rupture of membranes</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>170</VL>
<PG>1359-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vergani-1997" MODIFIED="2011-04-07 11:10:21 +0100" MODIFIED_BY="Jill Hampson" NAME="Vergani 1997" TYPE="JOURNAL_ARTICLE">
<AU>Vergani P, Locatelli A, Strobelt N, Mariani S, Cavallone M, Arosio P, et al</AU>
<TI>Amnioinfusion for prevention of pulmonary hypoplasia in second-trimester rupture of membranes</TI>
<SO>American Journal of Perinatology</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>6</NO>
<PG>325-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vintzileos-1985" MODIFIED="2011-04-08 11:21:05 +0100" MODIFIED_BY="Lynn Hampson" NAME="Vintzileos 1985" TYPE="JOURNAL_ARTICLE">
<AU>Vintzileos AM, Campbell WA, Nochimson DJ, Weinbaum PJ</AU>
<TI>Degree of oligohydramnios and pregnancy outcome in patients with premature rupture of membranes</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1985</YR>
<VL>66</VL>
<NO>2</NO>
<PG>162-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-03-17 14:44:29 +0000" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Hofmeyr-1995" NAME="Hofmeyr 1995" TYPE="OTHER">
<AU>Hofmeyr GJ</AU>
<TI>Amnioinfusion for preterm prelabour rupture of membranes [revised 22 April 1993]</TI>
<SO>In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Database of Systematic Reviews [database on disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software; 1995</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-1998b" MODIFIED="2014-03-17 14:44:29 +0000" MODIFIED_BY="Heather Maxwell" NAME="Hofmeyr 1998b" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ</AU>
<TI>Amnioinfusion for preterm rupture of membranes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-03-10 10:37:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-10 10:37:37 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000942"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2011" MODIFIED="2014-03-17 14:37:19 +0000" MODIFIED_BY="Heather Maxwell" NAME="Hofmeyr 2011" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Essilfie-Appiah G, Lawrie TA</AU>
<TI>Amnioinfusion for preterm premature rupture of membranes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2014-01-13 15:25:38 +0000" MODIFIED_BY="Leanne V Jones">
<IDENTIFIER MODIFIED="2014-01-13 15:25:38 +0000" MODIFIED_BY="Leanne V Jones" TYPE="DOI" VALUE="10.1002/14651858.CD000942.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-11-03 11:45:19 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-03-26 11:13:47 +0000" MODIFIED_BY="Leanne V Jones">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-03-26 11:13:47 +0000" MODIFIED_BY="Leanne V Jones" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-10-28 06:30:00 +0100" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Gonzalez-2001">
<CHAR_METHODS MODIFIED="2011-04-04 09:48:29 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial. Type of randomisation not specified. Abstract only.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-28 06:29:51 +0100" MODIFIED_BY="Denise Atherton">
<P>44 pregnant women with gestational ages from 189-258 days (24 in amnioinfusion group and 20 controls).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-23 11:37:52 +0000" MODIFIED_BY="[Empty name]">
<P>Amnioinfusion versus no amnioinfusion. Inclusion and exclusion criteria not specified.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-23 11:39:08 +0000" MODIFIED_BY="[Empty name]">
<P>Fetal heart rate variability, mode of delivery, cord arterial pH and perinatal morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-28 06:30:00 +0100" MODIFIED_BY="[Empty name]">
<P>This is an abstract only; we are not aware of any published final results. The abstract results are presented as percentages only without denominators and so could not be used in this review. Amnioinfusion reduced the percentage of caesarean sections done for fetal distress compared with the control group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-17 15:14:04 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Nageotte-1985">
<CHAR_METHODS MODIFIED="2011-10-06 10:36:43 +0100" MODIFIED_BY="Denise Atherton">
<P>'Assigned in a random fashion.'</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-05-22 16:41:06 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: spontaneous premature rupture of membranes; gestational age 26 to 35 weeks; decreased or absent amniotic fluid; vertex presentation; no gross fetal anomalies.</P>
<P>Exclusion criteria: premature labour on admission; vaginal bleeding; previous caesarean section and no desire for trial of labour; antepartum fetal distress; consent refused.</P>
<P>1 woman with twin pregnancy and 1 with previous caesarean section were allocated to the amnioinfusion group.</P>
<P>Of 66 women allocated, 3 were excluded for a change from the vertex presentation at the time of labour, and 2 for antepartum fetal distress. Of the remainder, 29 were allocated to amnioinfusion and 32 to the control group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-07 10:37:54 +0000" MODIFIED_BY="[Empty name]">
<P>Labour commenced spontaneously, or induced for confirmed fetal pulmonary maturity or infection. All women had fetal scalp electrodes and uterine pressure catheters placed as early in labour as possible. Amnioinfusion with warmed saline at 10 mL per minute for 1 hour (repeated if a large volume of fluid was lost), then 3 mL per minute (total volume infused mean 1160, range 735-1650 mL); compared with no amnioinfusion.</P>
<P>Caesarean section was performed for persistent late decelerations; recurrent severe variable decelerations; recurrent or uncorrectable prolonged decelerations (no mention of fetal scalp blood sampling).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-17 15:14:04 +0000" MODIFIED_BY="Heather Maxwell">
<P>Amnionitis (2 of the following: fever 38 degrees celsius or more; leucocytosis &gt; 15,000 per microlitre; foul-smelling amniotic fluid; uterine tenderness); intrapartum fetal heart rate tracings, evaluated in a blinded manner; endometritis (postpartum fever &gt; 38 degrees celsius twice 4 hours apart, and uterine tenderness or foul-smelling lochia); Apgar scores; umbilical cord arterial and venous pH; neonatal morbidity and mortality.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Long Beach, California, USA. March 1984 to March 1985.</P>
<P>Of 66 women allocated, 5 (7.6%) were excluded, 3 for a change from the vertex presentation at the time of labour, and 2 for antepartum fetal distress.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-07 10:37:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Puertas-2007">
<CHAR_METHODS MODIFIED="2011-06-17 12:31:17 +0100" MODIFIED_BY="Denise Atherton">
<P>Random allocation to 2 groups using a random number table and opaque sealed envelopes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-23 10:28:30 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: women with preterm premature rupture of membranes between 27 and 35 weeks of gestation; included if labour had begun spontaneously or after induction.<BR/>Exclusion criteria: women with multiple gestation, presentation other than cephalic, cervical dilatation &gt; 5 cm, cardiotocography signs compatible with non-reassuring fetal status, meconium-stained amniotic fluid, umbilical cord prolapse, uterine scarring, placenta praevia, premature detachment of the placenta, any vaginal bleeding of unknown cause, presence of oligohydramnios (amniotic fluid index &lt; 5) prior to premature rupture of the membranes, maternal infection that could be transmitted to the fetus (human immunodeficiency virus and herpes simplex virus), fetal anomalies incompatible with life, or any known obstetric or maternal complication other than premature rupture of membranes.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-07 10:37:59 +0000" MODIFIED_BY="[Empty name]">
<P>Intrapartum transcervical amnioinfusion versus a control group that had an intrauterine pressure catheter inserted but without amnioinfusion. Physiological saline at 37 degree celsius, at a rate of 600 mL/hr during the first hour. After 1 hour, amniotic fluid index was determined, and if amniotic fluid index was greater than 15, amnioinfusion was stopped. In all other women in the study group amnioinfusion continued at a rate of 180 mL/hr until the cervix was completely dilated. Fetal heart rate and uterine activity were recorded continuously throughout labour. All women who were group B streptococcus carriers received prophylactic intrapartum antibiotics.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-23 10:36:01 +0000" MODIFIED_BY="[Empty name]">
<P>Mode of delivery, PH and arterial blood concentrations, neonatal morbidity, puerperal morbidity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-17 12:32:19 +0100" MODIFIED_BY="Denise Atherton">
<P>More group B streptococcal carriers in control group (14 women versus 7 women).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-13 11:49:59 +0000" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Singla-2010">
<CHAR_METHODS MODIFIED="2011-06-17 12:32:51 +0100" MODIFIED_BY="Denise Atherton">
<P>Randomised controlled trial conducted in Delhi, India between August 2005 and 2007.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-13 11:49:59 +0000" MODIFIED_BY="Denise Atherton">
<P>60 women with singleton pregnancies (30 in each group) between 26 and 33 + 6 weeks' gestation with amniotic fluid index less than the 5th percentile. Excluded if evidence of chorioamnionitis, placental or fetal anomalies or active labour. Diagnosis of preterm rupture of membranes was made via the litmus paper test and confirmed using ultrasound.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-17 12:33:23 +0100" MODIFIED_BY="Denise Atherton">
<P>Transcervical amnioinfusion with normal saline repeated weekly if amniotic fluid index &lt; 5 versus no amnioinfusion. All women received bed rest, antibiotics and steroids.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-06 10:38:03 +0100" MODIFIED_BY="Denise Atherton">
<P>Preterm rupture of membranes to delivery interval; neonatal outcome including birthweight, intrapartum fetal distress defined as persistent tachycardia and recurrent, late or severe decelerations; early neonatal sepsis; neonatal mortality; causes of neonatal mortality; mode of delivery; postpartum sepsis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-17 12:37:28 +0100" MODIFIED_BY="Denise Atherton">
<P>No loss to follow-up. Baseline characteristics were similar between groups. 5 women received amnioinfusion twice, 1 woman received it 3 times.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-03-07 10:23:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tranquilli-2005">
<CHAR_METHODS MODIFIED="2014-01-13 11:50:31 +0000" MODIFIED_BY="Denise Atherton">
<P>Randomised controlled trial using opaque sealed envelopes and a computer random-number generator. 44 women met inclusion criteria, 4 refused to participate and 6 delivered before randomisation, leaving 34 women to be randomised.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-23 12:12:55 +0000" MODIFIED_BY="[Empty name]">
<P>Pregnant women included if: singleton pregnancies complicated by preterm premature rupture of membranes, gestational age between 24 and 33 weeks, evidence of preterm premature rupture of membrane within 24 hours of admission, oligohydramnios, absence of uterine contractions at the time of hospitalisation, no placental anomalies or major structural fetal anomalies and normal cardiotocography at the time of admission. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-07 10:23:01 +0000" MODIFIED_BY="[Empty name]">
<P>17 women were allocated to amnioinfusion and 17 to no amnioinfusion. All women received bedrest and antibiotic prophylaxis and corticosteroid therapy. Prophylactic tocolytic treatment was administered if there were no clinical signs of chorioamnionitis or placental abruption. Women in the treatment group received weekly serial amnioinfusion if the amniotic fluid index fell below the 5th centile and/or a median pocket of amniotic fluid was &lt; 2 cm. The mean volume infused was 250 mL N/saline (range 120-350 mL), the aim was to restore the amniotic fluid index to &gt; 10th percentile. The amniotic fluid index was measured after the procedure and it was repeated after 24 hours and at least once weekly. If amniotic fluid index was &#8804; 5, the amnioinfusion was repeated weekly until 27 weeks of gestation. A non-stress test was performed daily. Caesarean section was done for chorioamnionitis and fetal distress (defined as persistent tachycardia with reduced variability, recurrent late or severe variable decelerations).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-06 10:38:48 +0100" MODIFIED_BY="Denise Atherton">
<P>Birthweight; admission to neonatal intensive care unit; gestational age at delivery (weeks); pulmonary hypoplasia diagnosed on the basis of strict clinical and radiological criteria at 1 and 3 months after delivery; abnormal neurological outcomes. The preterm premature rupture of membrane-delivery interval was also determined.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-17 12:46:25 +0100" MODIFIED_BY="Denise Atherton">
<P>Study conducted at the Salesi Mothers' and Children's Hospital, Ancona, Italy, from January-December 2002.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-03-17 15:14:20 +0000" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-06-17 12:46:34 +0100" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-De-Santis-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-17 12:46:34 +0100" MODIFIED_BY="Denise Atherton">
<P>The quality of the randomisation process was poor. Women were by chance admitted into 1 of the 2 divisions of the department of obstetrics and gynaecology. Among the 71 women who were included in the study, 37 underwent serial amnioinfusion and 34 were used as controls. Also included in the study were women who underwent preterm rupture of membrane after amniocentesis for prenatal diagnosis. 10 patients (27.0%) in the amnioinfusion group and 8 patients (23.5%) in the control group. The study is also limited by the long period in which it was performed due to the low prevalence of this disease. The control group was selected without proper randomisation therefore bias could not be excluded during the selection process.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-17 12:48:22 +0100" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Gowri-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-17 12:48:22 +0100" MODIFIED_BY="Denise Atherton">
<P>Randomised controlled trial of amnioinfusion versus no amnioinfusion for oligohydramnios. Small numbers (9 controls versus 8 study participants), only 3 study participants who received amnioinfusion had premature rupture of membranes and these outcome data were not extractable from totals.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-17 12:49:20 +0100" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Locatelli-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-17 12:49:20 +0100" MODIFIED_BY="Denise Atherton">
<P>The study was not a randomised controlled trial. All singleton pregnancies with preterm premature rupture of membranes at &lt; 26 weeks' gestation and lasting &gt; 4 days between January 1991 and June 1998 were included. Consenting women with persistent (&gt; 4 days) oligohydramnios (maximum cord-free pocket of amniotic fluid volume less or equal to 2 cm) received serial transabdominal amnioinfusions to maintain an amniotic pocket &gt; 2 cm. The pregnancy, neonatal, and long-term neurological outcomes of the cases that spontaneously maintained a median amniotic fluid pocket &gt; 2 cm (amnioinfusion-not-necessary group) were compared with those of women with oligohydramnios who underwent amnioinfusion but continued to have a median amniotic fluid pocket after preterm premature rupture of membranes (amniotic fluid pocket less or equal to 2 cm/persistent oligohydramnios group) and with those of women in whom oligohydramnios was alleviated by amnioinfusion for at least 48 hours (successful amnioinfusion group).</P>
<P>The study also incorporated 18 cases that had been previously reported in <LINK REF="REF-Vergani-1997" TYPE="REFERENCE">Vergani 1997</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mino-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study population were women with ruptured membranes at term, not preterm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 15:12:36 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Roberts_x003a_-AMIPROM">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 15:12:36 +0000" MODIFIED_BY="Heather Maxwell">
<P>Excluded because even though this is a randomised controlled trial involving preterm premature rupture of membrane and amnioinfusion, the gestational ages when the preterm premature rupture of membrane occurred were in the 2nd trimester of pregnancy. There are no reported data for 3rd trimester outcomes. This was a prospective non-blinded randomised controlled trial with randomisation stratified for pregnancies where the membranes ruptured between 16 + 0 and 19 + 6 weeks' gestation and 20 + 0 and 23 + 6 weeks' gestation to minimise the risk of random imbalance in gestational age distribution between randomised groups. This study was carried out in 4 UK hospital-based Fetal Medicine Units (Liverpool Women&#8217;s NHS Trust, St. Mary&#8217;s Hospital Manchester, Birmingham Women&#8217;s NHS Foundation Trust, Wirral University Hospitals Trust). Participants were randomly allocated to either serial weekly trans-abdominal amnioinfusions if the deepest pool of amniotic fluid was &lt; 2 cm or expectant management until 37 weeks of pregnancy. Short-term maternal, pregnancy and neonatal and long-term outcomes for the child were studied. Long-term respiratory morbidity was assessed using validated respiratory questionnaires at 6, 12 and 18 months of age and infant lung function test at around 12 months of age. Neurodevelopment was assessed using Bayley&#8217;s Scale of Infant Development II at corrected age of 2.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-17 15:14:20 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Vergani-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-17 15:14:20 +0000" MODIFIED_BY="Heather Maxwell">
<P>Excluded because even though this is an randomised controlled trial involving preterm premature rupture of membrane and amnioinfusion, the gestational ages to be considered are preterm premature rupture of membranes that occurred in the 2nd trimester of pregnancy (&lt; 24 weeks). The study will consider singleton pregnancies, early spontaneous preterm premature rupture of membrane &lt; 24.3 weeks, oligohydramnios (deepest vertical pocket &lt; 2 cm) for at least 4 days and no longer than 15 days at enrolment. The study is open and will be run through a dedicated password protected website, and with a minimal number of outcome measures. Primary outcomes include survival until discharge from the neonatal intensive care unit, while secondary outcomes include latency time from preterm premature rupture of membrane to delivery, gestational age at birth, indication for delivery, number of days of ventilatory support, serious neurologic morbidity, neonatal sepsis prevalence, need for oxygen at 36 weeks post-conception. Statistics: 38 patients in each arm are necessary to show an increase in neonatal survival from 10% to 40%, with a power of 0.80 and alpha = 0.05. An interim analysis after recruitment of 75% of the study population will be held in order to re-calculate sample size according to the difference between the groups in latency time as the main secondary outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-03-23 12:56:59 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-01-13 11:56:03 +0000" MODIFIED_BY="Denise Atherton" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-03-26 11:13:47 +0000" MODIFIED_BY="Leanne V Jones">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-06-17 12:46:28 +0100" MODIFIED_BY="Denise Atherton" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:36:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2001">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-28 09:23:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nageotte-1985">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-17 12:32:21 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Puertas-2007">
<DESCRIPTION>
<P>Random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-25 09:59:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Singla-2010">
<DESCRIPTION>
<P>Computer-generated random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-17 12:46:28 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Tranquilli-2005">
<DESCRIPTION>
<P>Computer-generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-03-26 11:13:47 +0000" MODIFIED_BY="Leanne V Jones" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:36:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2001">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-28 09:23:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nageotte-1985">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-17 12:32:22 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Puertas-2007">
<DESCRIPTION>
<P>Opaque sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-26 11:13:47 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Singla-2010">
<DESCRIPTION>
<P>Not described: "To exclude observer bias, randomisation was performed ....using a computer generated random number table..." There was no mention of allocation concealment (e.g. sealed opaque envelopes).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-17 12:46:29 +0100" MODIFIED_BY="Denise Atherton" RESULT="YES" STUDY_ID="STD-Tranquilli-2005">
<DESCRIPTION>
<P>Opaque sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-01-30 11:13:27 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-01-30 11:13:12 +0000" MODIFIED_BY="Leanne V Jones" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-30 11:11:24 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2001">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-30 11:12:42 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Nageotte-1985">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-30 11:12:51 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Puertas-2007">
<DESCRIPTION>
<P>Not described. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-30 11:13:01 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Singla-2010">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-30 11:13:12 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Tranquilli-2005">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-01-30 11:13:14 +0000" MODIFIED_BY="Leanne V Jones" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-01-30 11:11:27 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2001">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-01-30 11:11:39 +0000" MODIFIED_BY="Leanne V Jones" RESULT="YES" STUDY_ID="STD-Nageotte-1985">
<DESCRIPTION>
<P>Fetal heart rate tracings evaluated in a blinded manner.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-01-30 11:12:06 +0000" MODIFIED_BY="Leanne V Jones" RESULT="YES" STUDY_ID="STD-Puertas-2007">
<DESCRIPTION>
<P>Partial blinding. Changes in fetal heart rate analysed with the Cabaniss classification by an independent investigator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-01-30 11:13:03 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Singla-2010">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-01-30 11:13:14 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Tranquilli-2005">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-03-07 10:23:24 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 11:37:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2001">
<DESCRIPTION>
<P>Abstract only, insufficient detail provided for assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-17 12:31:13 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Nageotte-1985">
<DESCRIPTION>
<P>5 post-randomisation exclusions: 3 for non-vertex presentation and 2 for fetal distress.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-07 10:21:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puertas-2007">
<DESCRIPTION>
<P>Outcome data complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-25 10:05:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Singla-2010">
<DESCRIPTION>
<P>No loss to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-03-07 10:23:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tranquilli-2005">
<DESCRIPTION>
<P>Outcome data were complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-03-07 10:22:12 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:37:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2001">
<DESCRIPTION>
<P>Abstract only, insufficient detail provided for assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-13 15:18:51 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Nageotte-1985">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 10:21:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Puertas-2007">
<DESCRIPTION>
<P>No selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 10:22:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Singla-2010">
<DESCRIPTION>
<P>No selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 12:41:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tranquilli-2005">
<DESCRIPTION>
<P>Authors do not report mode of delivery, Apgar scores or cord arterial pH.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-03-07 10:23:27 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 11:36:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gonzalez-2001">
<DESCRIPTION>
<P>Abstract only, insufficient detail provided for assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-13 15:18:54 +0000" MODIFIED_BY="Leanne V Jones" RESULT="UNKNOWN" STUDY_ID="STD-Nageotte-1985">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-17 12:32:41 +0100" MODIFIED_BY="Denise Atherton" RESULT="UNKNOWN" STUDY_ID="STD-Puertas-2007">
<DESCRIPTION>
<P>More group B streptococcal carriers in control group (14 women versus 7 women).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 10:22:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Singla-2010">
<DESCRIPTION>
<P>None other bias was noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 10:23:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tranquilli-2005">
<DESCRIPTION>
<P>No other bias noted.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-03-18 11:07:57 +0000" MODIFIED_BY="Heather Maxwell">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-03-18 11:07:57 +0000" MODIFIED_BY="Heather Maxwell" NO="1">
<TITLE MODIFIED="2011-03-28 12:32:30 +0100" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="5" ROWS="9">
<TR>
<TD COLSPAN="5">
<P>
<B>Transabdominal amnioinfusion compared with no amnioinfusion for preterm rupture of membranes (PROM)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Patient or population: pregnant women with PROM</B>
</P>
<P>
<B>Settings: hospital</B>
</P>
<P>
<B>Intervention: transabdominal amnioinfusion</B>
</P>
<P>
<B>Comparison: no amnioinfusion</B>
</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Neonatal death</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.30 (0.14 - 0.66)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>94 (two studies)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Risk of neonatal death in the amnioinfusion group was 127 per 1000 compared to 426 per 1000 in the control group.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Neonatal sepsis/infection</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.26</B> <B>(0.11 - 0.61)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>60 (one study*)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>*Sepsis defined as micro-erythrocyte sedimentation rate &gt; 5 mm, total leucocyte count &lt; 5000, CRP &gt; 6 mg/dL, platelet count &lt; 100,000 or a positive blood culture within the first 48 hours.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pulmonary hypoplasia</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.22 (0.06 - 0.88)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>34 (one study)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Pulmonary hypoplasia was diagnosed according to strict clinical and radiological criteria, however, this study was small and blinding to group allocation was not described and so we downgraded this evidence from moderate to low. More evidence is needed.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Maternal puerperal sepsis</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR</B> <B>0.20 (0.05 - 0.84)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>60 (one study**)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>**Defined as fever &gt; 38° C and a positive high vaginal swab culture.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.</P>
<P>
<B>CI: confidence interval; CRP: C-reactive protein; RR: risk ratio</B>
<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-01-14 12:54:22 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-01-14 12:54:22 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Transcervical amnioinfusion for preterm rupture of membranes</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9092022632486987" CI_START="0.2993962193342931" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.041339491870078626" LOG_CI_START="-0.5237536880698574" LOG_EFFECT_SIZE="-0.28254658996996806" METHOD="MH" MODIFIED="2011-03-23 11:20:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.021683078414932846" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="2.29587414573683">
<NAME>Persistant variable decelerations</NAME>
<GROUP_LABEL_1>Amnioinfusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9092022632486987" CI_START="0.2993962193342931" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="23" LOG_CI_END="-0.041339491870078626" LOG_CI_START="-0.5237536880698574" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="14" O_E="0.0" SE="0.2833724868365343" STUDY_ID="STD-Puertas-2007" TOTAL_1="43" TOTAL_2="43" VAR="0.08029996629592182" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.572109667628261" CI_START="-1.827890332371739" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-03-23 11:20:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.7981390886722515E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="32" UNITS="" WEIGHT="100.0" Z="3.7458082410091995">
<NAME>Severe variable decelerations per hour in first stage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="-0.5721096676282609" CI_START="-1.827890332371739" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="1.4" ORDER="1" SD_1="0.2" SD_2="1.8" SE="0.3203580970489549" STUDY_ID="STD-Nageotte-1985" TOTAL_1="29" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.1412720415206064" CI_END="1.2174323183982516" CI_START="0.25747533639550924" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5598739105533982" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" I2="6.597575589708032" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.08544482650826986" LOG_CI_START="-0.5892643657697215" LOG_EFFECT_SIZE="-0.25190976963072587" METHOD="MH" MODIFIED="2011-03-23 11:20:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.34279063313768565" P_Q="0.6087426667103701" P_Z="0.14331795027683508" Q="0.2620099785968707" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.024135880105898424" TOTALS="SUB" TOTAL_1="115" TOTAL_2="118" WEIGHT="200.0" Z="1.4635463144144565">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="1.5976925102118271" CI_END="1.7318381206551519" CI_START="0.24628050391175615" DF="1" EFFECT_SIZE="0.6530834288577069" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="37.409733499506935" ID="CMP-001.03.01" LOG_CI_END="0.23850729496088074" LOG_CI_START="-0.6085699664746148" LOG_EFFECT_SIZE="-0.18503133575686706" MODIFIED="2011-03-23 10:59:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.20623057327773753" P_Z="0.3918597792021953" STUDIES="2" TAU2="0.21562410202434687" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="0.8562495314305252">
<NAME>Caesarean section overall</NAME>
<DICH_DATA CI_END="1.3974320796263402" CI_START="0.07112743761259913" EFFECT_SIZE="0.31527093596059114" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.14533070875143397" LOG_CI_START="-1.1479628366100854" LOG_EFFECT_SIZE="-0.5013160639293257" ORDER="2" O_E="0.0" SE="0.7596870304516546" STUDY_ID="STD-Nageotte-1985" TOTAL_1="29" TOTAL_2="32" VAR="0.5771243842364532" WEIGHT="31.230995689421025"/>
<DICH_DATA CI_END="1.914525079526802" CI_START="0.4316716922799474" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.282061059808156" LOG_CI_START="-0.3648464301246061" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="3" O_E="0.0" SE="0.3799966618302248" STUDY_ID="STD-Puertas-2007" TOTAL_1="43" TOTAL_2="43" VAR="0.1443974630021142" WEIGHT="68.76900431057898"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5487628266912903" CI_START="0.11859367116923067" DF="0" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.18998491618036265" LOG_CI_START="-0.9259384867695515" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2011-03-23 11:00:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.19614947000819194" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.00000000000001" Z="1.2925999121762373">
<NAME>Caesarean section for fetal distress</NAME>
<DICH_DATA CI_END="1.5487628266912903" CI_START="0.11859367116923067" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.18998491618036265" LOG_CI_START="-0.9259384867695515" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2011-03-23 11:00:26 +0000" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.6554989308027126" STUDY_ID="STD-Puertas-2007" TOTAL_1="43" TOTAL_2="43" VAR="0.42967884828349945" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7278713937859034" CI_END="1.6883110137872246" CI_START="0.4401812789462892" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8620689655172413" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="63.3413803056111" I2_Q="59.140031823198505" ID="CMP-001.04" LOG_CI_END="0.22745245362237068" LOG_CI_START="-0.35636843207620766" LOG_EFFECT_SIZE="-0.0644579892269185" METHOD="MH" MODIFIED="2011-03-23 11:20:08 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.09861070858617671" P_Q="0.11772120186437007" P_Z="0.6651687915374926" Q="2.4473832081145774" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="86" WEIGHT="200.0" Z="0.4327880022636152">
<NAME>Forceps/vacuum assisted delivery</NAME>
<GROUP_LABEL_1>Amnioinfusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.477625967199903" CI_START="0.5812015288277836" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.3940357440731938" LOG_CI_START="-0.23567325197794425" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2011-03-23 11:11:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.622081883610919" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.4929019324086204">
<NAME>Overall</NAME>
<DICH_DATA CI_END="2.4776259671999035" CI_START="0.5812015288277835" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.3940357440731939" LOG_CI_START="-0.23567325197794434" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2011-03-23 11:11:59 +0000" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.36989418139024116" STUDY_ID="STD-Puertas-2007" TOTAL_1="43" TOTAL_2="43" VAR="0.13682170542635663" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0026701966680087" CI_START="0.006164609146771197" DF="0" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.3016094347851477" LOG_CI_START="-2.2100944536637974" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2011-03-23 11:12:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1364208271044518" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.4892527416304284">
<NAME>For fetal distress</NAME>
<DICH_DATA CI_END="2.0026701966680087" CI_START="0.006164609146771197" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3016094347851477" LOG_CI_START="-2.2100944536637974" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2011-03-23 11:12:33 +0000" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="1.4753872972096773" STUDY_ID="STD-Puertas-2007" TOTAL_1="43" TOTAL_2="43" VAR="2.1767676767676765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.328112301359495" CI_START="0.0326873755400448" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.27586206896551724" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="100.00000000000001" ID="CMP-001.05" LOG_CI_END="0.3670039255845578" LOG_CI_START="-1.485619947398583" LOG_EFFECT_SIZE="-0.5593080109070125" METHOD="MH" MODIFIED="2011-03-23 11:20:06 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.23663955468533182" Q="4.163233166771491E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="32" WEIGHT="100.0" Z="1.183428081251392">
<NAME>1 minute Apgar score &lt; 4</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="2.328112301359495" CI_START="0.0326873755400448" EFFECT_SIZE="0.27586206896551724" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3670039255845578" LOG_CI_START="-1.485619947398583" LOG_EFFECT_SIZE="-0.5593080109070125" ORDER="4" O_E="0.0" SE="1.0882404336263702" STUDY_ID="STD-Nageotte-1985" TOTAL_1="29" TOTAL_2="32" VAR="1.1842672413793103" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.14315798557364537" CI_START="0.0768420144263535" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10999999999999943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2011-03-23 11:20:03 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="7.921435376295027E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="32" UNITS="" WEIGHT="100.0" Z="6.502084929754032">
<NAME>Umbilical arterial pH</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.14315798557364537" CI_START="0.0768420144263535" EFFECT_SIZE="0.10999999999999943" ESTIMABLE="YES" MEAN_1="7.34" MEAN_2="7.23" ORDER="5" SD_1="0.05" SD_2="0.08" SE="0.016917650444187696" STUDY_ID="STD-Nageotte-1985" TOTAL_1="29" TOTAL_2="32" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.110070290833572" CI_START="0.05630274093099782" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.045350479646684205" LOG_CI_START="-1.249470462302609" LOG_EFFECT_SIZE="-0.6020599913279624" METHOD="MH" MODIFIED="2011-03-23 11:20:02 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.06835332660335058" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.8226703960454087">
<NAME>Umbilical pH &#8804; 7.20</NAME>
<GROUP_LABEL_1>Amnioinfusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1100702908335718" CI_START="0.05630274093099784" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.045350479646684115" LOG_CI_START="-1.2494704623026087" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="12" O_E="0.0" SE="0.7605842307680479" STUDY_ID="STD-Puertas-2007" TOTAL_1="43" TOTAL_2="43" VAR="0.5784883720930232" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3413119605858261" CI_START="0.18638467958700003" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.12752979724352442" LOG_CI_START="-0.7295897885714868" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2011-03-23 11:58:19 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.1685980305442233" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.3767225939811645">
<NAME>Neonatal morbidity</NAME>
<GROUP_LABEL_1>Amnioinfusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3413119605858261" CI_START="0.18638467958700003" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.12752979724352442" LOG_CI_START="-0.7295897885714868" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-03-23 11:15:29 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1685980305442233" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.3767225939811645">
<NAME>Overall</NAME>
<DICH_DATA CI_END="1.3413119605858266" CI_START="0.18638467958699995" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.12752979724352456" LOG_CI_START="-0.7295897885714869" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="13" O_E="0.0" SE="0.5034762875181147" STUDY_ID="STD-Puertas-2007" TOTAL_1="43" TOTAL_2="43" VAR="0.25348837209302333" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.7693725899616615" CI_START="0.052761287233447" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5517241379310345" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.761128586893526" LOG_CI_START="-1.2776846173795884" LOG_EFFECT_SIZE="-0.2582780152430313" METHOD="MH" MODIFIED="2011-03-23 11:21:26 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.6194861766594633" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="32" WEIGHT="100.0" Z="0.49657870256466813">
<NAME>Neonatal death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="5.7693725899616615" CI_START="0.052761287233447" EFFECT_SIZE="0.5517241379310345" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.761128586893526" LOG_CI_START="-1.2776846173795884" LOG_EFFECT_SIZE="-0.2582780152430313" ORDER="6" O_E="0.0" SE="1.197608968478155" STUDY_ID="STD-Nageotte-1985" TOTAL_1="29" TOTAL_2="32" VAR="1.4342672413793103" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0024925457698692756" CI_END="2.1780271956569095" CI_START="0.0581662771073571" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3559322033898305" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.33806329821589454" LOG_CI_START="-1.2353287320323445" LOG_EFFECT_SIZE="-0.4486327169082249" METHOD="MH" MODIFIED="2011-03-28 13:11:25 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9601818511165895" P_Q="1.0" P_Z="0.26368764946464107" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="75" WEIGHT="100.0" Z="1.1177175815333755">
<NAME>Maternal puerperal sepsis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="3.3417930664224986" CI_START="0.04048385845900427" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5239795536084553" LOG_CI_START="-1.3927181022058803" LOG_EFFECT_SIZE="-0.4343692742987126" MODIFIED="2011-03-25 11:01:03 +0000" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="1.1258776908317545" STUDY_ID="STD-Nageotte-1985" TOTAL_1="29" TOTAL_2="32" VAR="1.2676005747126435" WEIGHT="65.53672316384181"/>
<DICH_DATA CI_END="7.961364031061661" CI_START="0.013956290740833538" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009874823623856" LOG_CI_START="-1.8552299918017108" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-03-25 11:01:03 +0000" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Puertas-2007" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="34.463276836158194"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-01-14 12:54:22 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Transabdominal amnioinfusion for preterm rupture of membranes</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8804951977975177" CI_START="0.08447537871337824" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.055273008323310016" LOG_CI_START="-1.0732698525538154" LOG_EFFECT_SIZE="-0.5642714304385626" METHOD="MH" MODIFIED="2011-03-25 10:49:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.02979538669275648" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="2.1727998223814935">
<NAME>Fetal distress</NAME>
<GROUP_LABEL_1>Amnioinfusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amnioinfusion</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8804951977975177" CI_START="0.08447537871337824" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.055273008323310016" LOG_CI_START="-1.0732698525538154" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2011-03-25 10:49:22 +0000" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.5979763854666483" STUDY_ID="STD-Singla-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.35757575757575755" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.497160277352418" CI_END="1.6499210314020816" CI_START="-2.6341385932094123" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4921087809036655" ESTIMABLE="YES" I2="59.954512769190885" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2011-03-25 10:54:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11405206076079122" P_Q="1.0" P_Z="0.6525077843757369" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.5857968627450998" TOTALS="YES" TOTAL_1="47" TOTAL_2="47" UNITS="" WEIGHT="100.0" Z="0.4502810752240944">
<NAME>Gestational age at delivery (weeks)</NAME>
<GROUP_LABEL_1>Amnioinfusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours amnioinfusion</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2522547765632817" CI_START="-0.6522547765632802" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="31.7" MEAN_2="31.4" MODIFIED="2011-03-25 10:51:59 +0000" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="1.96" SD_2="1.8" SE="0.48585320142336547" STUDY_ID="STD-Singla-2010" TOTAL_1="30" TOTAL_2="30" WEIGHT="65.56048778679713"/>
<CONT_DATA CI_END="0.6890484022311472" CI_START="-4.689048402231148" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="29.0" MODIFIED="2011-03-23 13:28:43 +0000" MODIFIED_BY="[Empty name]" ORDER="39" SD_1="4.0" SD_2="4.0" SE="1.3719886811400708" STUDY_ID="STD-Tranquilli-2005" TOTAL_1="17" TOTAL_2="17" WEIGHT="34.43951221320287"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.04226102072718038" CI_END="0.4949029923693895" CI_START="0.12628737543245802" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.3054799202733359" LOG_CI_START="-0.8986400623825889" LOG_EFFECT_SIZE="-0.6020599913279624" METHOD="MH" MODIFIED="2011-03-25 10:55:37 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9790911828530051" P_Q="0.9791726554961707" P_Z="6.92805617685601E-5" Q="0.042094602352599694" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="64" TOTAL_2="64" WEIGHT="300.0" Z="3.978743060311558">
<NAME>Neonatal morbidity</NAME>
<GROUP_LABEL_1>Amnioinfusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6127531762254823" CI_START="0.11301790059892455" DF="0" EFFECT_SIZE="0.2631578947368421" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.21271442889085776" LOG_CI_START="-0.9468527643427627" LOG_EFFECT_SIZE="-0.5797835966168102" MODIFIED="2011-03-25 10:55:37 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.001963147350768825" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="3.0957516133428835">
<NAME>Neonatal sepsis/infection</NAME>
<DICH_DATA CI_END="0.6127531762254823" CI_START="0.11301790059892455" EFFECT_SIZE="0.2631578947368421" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" LOG_CI_END="-0.21271442889085776" LOG_CI_START="-0.9468527643427627" LOG_EFFECT_SIZE="-0.5797835966168102" MODIFIED="2011-03-25 10:55:37 +0000" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.4312364922878185" STUDY_ID="STD-Singla-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.18596491228070178" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8805033341715491" CI_START="0.056084644013126975" DF="0" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-0.05526899516568334" LOG_CI_START="-1.251156032385004" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2011-03-23 11:55:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03226379935248432" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="2.141126981738077">
<NAME>Pulmonary hypoplasia</NAME>
<DICH_DATA CI_END="0.8805033341715491" CI_START="0.056084644013126975" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.05526899516568334" LOG_CI_START="-1.251156032385004" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2011-03-23 11:55:54 +0000" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.7024699653989356" STUDY_ID="STD-Tranquilli-2005" TOTAL_1="17" TOTAL_2="17" VAR="0.4934640522875817" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.01243203236567" CI_START="0.031056949499322712" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.30372122147866387" LOG_CI_START="-1.5078412041345888" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2011-03-23 11:55:54 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.19265657248484336" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="1.302760404887337">
<NAME>Abnormal neurological outcome</NAME>
<DICH_DATA CI_END="2.01243203236567" CI_START="0.031056949499322712" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.30372122147866387" LOG_CI_START="-1.5078412041345888" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2011-03-23 11:55:54 +0000" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="1.0641207361838554" STUDY_ID="STD-Tranquilli-2005" TOTAL_1="17" TOTAL_2="17" VAR="1.1323529411764706" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.700185744111537" CI_START="0.04721297386826463" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.154786735782813" LOG_CI_START="-1.3259386432056748" LOG_EFFECT_SIZE="-0.7403626894942439" METHOD="MH" MODIFIED="2011-03-25 10:45:29 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.013210407642413638" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.00000000000001" Z="2.4780460975366774">
<NAME>Delivery within 7 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.700185744111537" CI_START="0.04721297386826463" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.154786735782813" LOG_CI_START="-1.3259386432056748" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2011-03-23 11:58:41 +0000" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.6879404277156282" STUDY_ID="STD-Tranquilli-2005" TOTAL_1="17" TOTAL_2="17" VAR="0.4732620320855615" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.9997652384680906" CI_START="-2.859765238468092" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5699999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2011-03-28 10:35:22 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.7446281947802761" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="99.99999999999999" Z="0.32573059481086214">
<NAME>Time to delivery (days)</NAME>
<GROUP_LABEL_1>Amnioinfusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.9997652384680906" CI_START="-2.859765238468092" EFFECT_SIZE="0.5699999999999994" ESTIMABLE="YES" MEAN_1="7.27" MEAN_2="6.7" MODIFIED="2011-03-25 10:58:01 +0000" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="7.53" SD_2="5.93" SE="1.7499123787588147" STUDY_ID="STD-Singla-2010" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.116759803760288" CI_START="0.8954477020330235" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.04795977372530101" LOG_CI_START="-0.04795977372530097" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2011-03-25 10:47:46 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="0.0">
<NAME>Admission to neonatal intensive care unit</NAME>
<GROUP_LABEL_1>Amnioinfusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.116759803760288" CI_START="0.8954477020330234" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.04795977372530101" LOG_CI_START="-0.047959773725301025" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-23 11:58:56 +0000" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.05634361698190113" STUDY_ID="STD-Tranquilli-2005" TOTAL_1="17" TOTAL_2="17" VAR="0.003174603174603177" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8623943816765636" CI_END="0.6617326766579257" CI_START="0.13600658268009988" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-0.17931741916956423" LOG_CI_START="-0.866440071391111" LOG_EFFECT_SIZE="-0.5228787452803376" METHOD="MH" MODIFIED="2011-03-28 13:08:38 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.35306959601677546" P_Q="1.0" P_Z="0.002854920910722744" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="47" WEIGHT="100.0" Z="2.982941999416209">
<NAME>Neonatal death</NAME>
<GROUP_LABEL_1>Amnioinfusion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amnioinfusion</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6127531762254823" CI_START="0.11301790059892455" EFFECT_SIZE="0.2631578947368421" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="19" LOG_CI_END="-0.21271442889085776" LOG_CI_START="-0.9468527643427627" LOG_EFFECT_SIZE="-0.5797835966168102" MODIFIED="2011-03-25 10:56:12 +0000" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.4312364922878185" STUDY_ID="STD-Singla-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.18596491228070178" WEIGHT="95.0"/>
<DICH_DATA CI_END="14.717663958438468" CI_START="0.06794556546636217" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1678388826597432" LOG_CI_START="-1.1678388826597432" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-23 12:33:19 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="1.3719886811400708" STUDY_ID="STD-Tranquilli-2005" TOTAL_1="17" TOTAL_2="17" VAR="1.8823529411764706" WEIGHT="5.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.6848152056728978" CI_END="285.324014159639" CI_START="-254.02158810447114" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="15.65121302758392" ESTIMABLE="YES" I2="40.64630965859485" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2011-09-24 17:36:10 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.19428593266685923" P_Q="1.0" P_Z="0.9094344094602168" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="17686.225490196084" TOTALS="YES" TOTAL_1="47" TOTAL_2="47" UNITS="" WEIGHT="99.99999999999999" Z="0.11375197542968772">
<NAME>Birthweight (grams)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours amnioinfusion</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="307.42847354753496" CI_START="-87.42847354753499" EFFECT_SIZE="110.0" ESTIMABLE="YES" MEAN_1="1430.0" MEAN_2="1320.0" MODIFIED="2011-03-25 10:59:22 +0000" MODIFIED_BY="[Empty name]" ORDER="29" SD_1="400.0" SD_2="380.0" SE="100.73066398404542" STUDY_ID="STD-Singla-2010" TOTAL_1="30" TOTAL_2="30" WEIGHT="68.01736034833353"/>
<CONT_DATA CI_END="214.30331563286393" CI_START="-584.3033156328639" EFFECT_SIZE="-185.0" ESTIMABLE="YES" MEAN_1="1373.0" MEAN_2="1558.0" MODIFIED="2011-09-24 17:36:10 +0100" MODIFIED_BY="[Empty name]" ORDER="37" SD_1="504.0" SD_2="672.0" SE="203.7299250305197" STUDY_ID="STD-Tranquilli-2005" TOTAL_1="17" TOTAL_2="17" WEIGHT="31.982639651666464"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8368732970249826" CI_START="0.047796960593911655" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-0.07734028940003874" LOG_CI_START="-1.3205997192719987" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" MODIFIED="2011-03-28 13:09:09 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.02753745405591836" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.2038136238604524">
<NAME>Maternal puerperal sepsis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>favours amnioinfusion</GRAPH_LABEL_1>
<GRAPH_LABEL_2>favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8368732970249826" CI_START="0.047796960593911655" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.07734028940003874" LOG_CI_START="-1.3205997192719987" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-03-25 10:56:48 +0000" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Singla-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.5333333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-03-26 11:13:48 +0000" MODIFIED_BY="Leanne V Jones">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-03-26 11:13:48 +0000" MODIFIED_BY="Leanne V Jones" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAT0AAAHrCAIAAAAynt34AAAVmklEQVR42u3dsa4kSZXG8SshIYw2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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-03-26 11:13:48 +0000" MODIFIED_BY="Leanne V Jones" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-03-18 11:17:45 +0000" MODIFIED_BY="Heather Maxwell">
<APPENDIX ID="APP-01" MODIFIED="2014-03-18 11:17:45 +0000" MODIFIED_BY="Heather Maxwell" NO="1">
<TITLE MODIFIED="2014-01-13 14:53:15 +0000" MODIFIED_BY="Leanne V Jones">Methods to be used in the next update</TITLE>
<APPENDIX_BODY MODIFIED="2014-03-18 11:17:45 +0000" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">Data collection and analysis</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Two review authors will independently assess for inclusion all the potential studies we identify as a result of the search strategy. We will resolve any disagreement through discussion or, if required, we will consult a third author.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management</HEADING>
<P>We will design a form to extract data. For eligible studies, at least two review authors will extract the data using the agreed form. We will resolve discrepancies through discussion or, if required, we will consult a third person. We will enter data into Review Manager software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) and check for accuracy.</P>
<P>When information regarding any of the above is unclear, we will attempt to contact authors of the original reports to provide further details.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies</HEADING>
<P>Two review authors will independently assess risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We will resolve any disagreement by discussion or by involving a third assessor.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>We will describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We will assess the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We will describe for each included study the method used to conceal allocation to interventions prior to assignment and will assess whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We will assess the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We will describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We will consider that studies are at low risk of bias if they were blinded, or if we judge that the lack of blinding would be unlikely to affect results. We will assess blinding separately for different outcomes or classes of outcomes.</P>
<P>We will assess the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We will describe for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We will assess blinding separately for different outcomes or classes of outcomes.</P>
<P>We will assess methods used to blind outcome assessment as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>We will describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We will state whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information is reported, or can be supplied by the trial authors, we will re-include missing data in the analyses which we undertake.</P>
<P>We will assess methods as:</P>
<UL>
<LI>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomisation);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias)</HEADING>
<P>We will describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We will assess the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>We will describe for each included study any important concerns we have about other possible sources of bias.</P>
<P>We will assess whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>low risk of other bias;</LI>
<LI>high risk of other bias;</LI>
<LI>unclear whether there is risk of other bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We will make explicit judgements about whether studies are at high risk of bias, according to the criteria given in the 
<I>Cochrane </I>

<I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we will assess the likely magnitude and direction of the bias and whether we consider it is likely to impact on the findings. We will explore the impact of the level of bias through undertaking sensitivity analyses - <I>see '</I>Sensitivity analysis'.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of treatment effect</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Dichotomous data</I>
</HEADING>
<P>For dichotomous data, we will present results as summary risk ratio with 95% confidence intervals.<I> </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>Continuous data</I>
</HEADING>
<P>For continuous data, we will use the mean difference if outcomes are measured in the same way between trials. We will use the standardised mean difference to combine trials that measure the same outcome, but use different methods.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unit of analysis issues</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>We will not consider cluster-randomised trials for inclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>We will not consider cross-over trials for inclusion.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dealing with missing data</HEADING>
<P>For included studies, we will note levels of attrition. We will explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes, we will carry out analyses, as far as possible, on an intention-to-treat basis, i.e. we will attempt to include all participants randomised to each group in the analyses, and all participants will be analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial will be the number randomised minus any participants whose outcomes are known to be missing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity</HEADING>
<P>We will assess statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² statistics. We will regard heterogeneity as substantial if an I² is greater than 30% and either the Tau² is greater than zero, or there is a low P value (&lt; 0.10) in the Chi² test for heterogeneity.<B> </B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting biases</HEADING>
<P>If there are 10 or more studies in the meta-analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it.<I>
<BR/>
</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis</HEADING>
<P>We will carry out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). We will use fixed-effect meta-analysis for combining data where it is reasonable to assume that studies are estimating the same underlying treatment effect: i.e. where trials are examining the same intervention, and the trials&#8217; populations and methods are judged sufficiently similar. If there is clinical heterogeneity sufficient to expect that the underlying treatment effects differ between trials, or if substantial statistical heterogeneity is detected, we will use random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials is considered clinically meaningful. The random-effects summary will be treated as the average range of possible treatment effects and we will discuss the clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically meaningful, we will not combine trials.</P>
<P>If we use random-effects analyses, the results will be presented as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I².</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis and investigation of heterogeneity</HEADING>
<P>If we identify substantial heterogeneity, we will investigate it using subgroup analyses and sensitivity analyses. We will consider whether an overall summary is meaningful, and if it is, use random-effects analysis to produce it.</P>
<P>We plan to carry out the following subgroup analyses.</P>
<OL>
<LI>Effects of transabdominal versus transcervical amnioinfusion on complications of preterm premature rupture of the fetal membranes.</LI>
<LI>Effects of transabdominal versus transcervical amnioinfusion at the various gestational ages in the third trimester.</LI>
</OL>
<P>The following outcomes will be used in subgroup analysis: persistent variable decelerations, Apgar scores, cord arterial pH at birth, neonatal morbidity including infection, lung hypoplasia, abnormal neurological outcomes and postural deformities, as well as perinatal mortality.</P>
<P>We will assess subgroup differences by interaction tests available within RevMan (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). We will report the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>Sensitivity analyses will be performed for aspects of the review that might affect the results, for example, where there is risk of bias associated with the quality of some of the included trials. Sensitivity analysis will be carried out to explore the effects of fixed-effect or random-effects analyses for outcomes with statistical heterogeneity and the effects of any assumptions made.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>